drugset

drugset / Trial / NCT03777332

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

NCT03777332 ↗

Phase 1 Completed 19 enrolled Apellis Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Safety Assessment of APL-2 in Patients with Geographic Atrophy

Timeline

Start: 2018-11-05
Primary completion: 2021-04-01
Completion: 2021-04-01

Publications

Wykoff CC, Holz FG, Chiang A, Boyer D, Dhoot DS, Loewenstein A, Mones J, Heier J, Abbey AM, Singerman LJ, Vajzovic L, Lin J, Li C, Vilupuru A, Baumal CR; OAKS, DERBY, and GALE Investigators. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. Am J Ophthalmol. 2025 Aug;276:350-364. doi: 10.1016/j.ajo.2025.04.016. Epub 2025 Apr 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegcetacoplan	Peptide	15 mg	Intravitreal

Indications